Aethl Bio Names Limb Salvage Researchers Armstrong and Zelen as Advisors

Aethl Bio said on October 19, 2026 that Dr. David G. Armstrong and Dr. Charles M. Zelen joined the Pittsburgh biomaterials company as advisors. Both researchers have spent their careers studying how to heal diabetic foot ulcers and prevent amputation. The appointments come as Aethl Bio moves its first wound dressing toward a planned 510(k) premarket notification with the U.S. Food and Drug Administration, EIN Presswire reported.

Armstrong and Zelen's Advisory Roles at Aethl Bio

Aethl Bio said Armstrong and Zelen will advise the company on clinical strategy, treatment application, research protocols and evidence generation for Nuvoxen, its first wound dressing.

Armstrong is Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC. He has authored more than 790 peer-reviewed papers and is Founding President of the American Limb Preservation Society. He is the youngest recipient of the American Diabetes Association's Roger Pecoraro Award and a recipient of the Karel Bakker Award.

"People living with diabetic foot disease need advances grounded in rigorous science and focused on preserving mobility and independence," Armstrong said. "As an advisor to Aethl Bio, I'll help guide clinical strategy and the development of meaningful research protocols, with the goal of giving patients more ulcer-free, hospital-free and activity-rich days."

Zelen is founder and president of the Professional Education and Research Institute in Roanoke, Virginia, and Podiatry Section Chief in the Department of Orthopedics at HCA LewisGale Medical Center. He is board-certified in foot surgery, reconstructive rearfoot and ankle surgery by the American Board of Foot and Ankle Surgery, and in podiatric medicine by the American Board of Podiatric Medicine. He performed some of the first randomized trials on amniotic membrane grafts in diabetic foot ulcers and has since led and co-authored many of the top multi-center trials of advanced wound biologics.

"Sound wound care research starts long before the first data point, with the right questions and a rigorous protocol," Zelen said. "As an advisor to Aethl Bio, I'll help make sure its research answers the questions clinicians and patients actually have."

Carmelo Montalvo, CEO of Aethl Bio, said: "Wound care has no shortage of products. What it lacks is evidence clinicians and patients can trust. Dr. Armstrong and Dr. Zelen helped build much of the evidence base this field relies on, and their guidance will shape how we build ours."

Aethl Bio's Funding and Wound Care Market Data

According to akta.pro company records, Aethl Bio has one funding round on record: a pre-seed of $200,000 in August 2025 with one investor. The company's total funding stands at $200,000, and its valuation estimate is under $10 million. Aethl Bio is pre-revenue, with a headcount range of 1-10, and was founded in 2025.

The same records list annual U.S. healthcare costs attributable to chronic wounds at $148 billion+, with 1 in 6 Medicare beneficiaries suffering from a chronic wound and 1 in 5 diabetic foot ulcers resulting in amputation.

Nuvoxen's Planned FDA Submission

Aethl Bio's wound dressing is in development, has not been cleared by the U.S. Food and Drug Administration, and is not available for sale. The company said the product is moving toward a planned 510(k) premarket notification with the agency. Aethl Bio's own announcement describes Nuvoxen as its first wound dressing.